The New England journal of medicine, 2022-03, Vol.386 (9), p.847-860
- Sadoff, Jerald
- Gray, Glenda
- Vandebosch, An
- Cárdenas, Vicky
- Shukarev, Georgi
- Grinsztejn, Beatriz
- Goepfert, Paul A
- Truyers, Carla
- Van Dromme, Ilse
- Spiessens, Bart
- Vingerhoets, Johan
- Custers, Jerome
- Scheper, Gert
- Robb, Merlin L
- Treanor, John
- Ryser, Martin F
- Barouch, Dan H
- Swann, Edith
- Marovich, Mary A
- Neuzil, Kathleen M
- Corey, Lawrence
- Stoddard, Jeffrey
- Hardt, Karin
- Ruiz-Guiñazú, Javier
- Le Gars, Mathieu
- Schuitemaker, Hanneke
- Van Hoof, Johan
- Struyf, Frank
- Douoguih, Macaya
2022
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Sadoff, Jerald
- Gray, Glenda
- Vandebosch, An
- Cárdenas, Vicky
- Shukarev, Georgi
- Grinsztejn, Beatriz
- Goepfert, Paul A
- Truyers, Carla
- Van Dromme, Ilse
- Spiessens, Bart
- Vingerhoets, Johan
- Custers, Jerome
- Scheper, Gert
- Robb, Merlin L
- Treanor, John
- Ryser, Martin F
- Barouch, Dan H
- Swann, Edith
- Marovich, Mary A
- Neuzil, Kathleen M
- Corey, Lawrence
- Stoddard, Jeffrey
- Hardt, Karin
- Ruiz-Guiñazú, Javier
- Le Gars, Mathieu
- Schuitemaker, Hanneke
- Van Hoof, Johan
- Struyf, Frank
- Douoguih, Macaya
- Titel
- Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
- Ist Teil von
- The New England journal of medicine, 2022-03, Vol.386 (9), p.847-860
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2022
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- The randomized trial assessing the efficacy of a single injection of the Ad26.COV2.S showed 56.3% vaccine efficacy beginning 14 days after injection and 52.9% efficacy more than 28 days after injection against moderate to severe–critical Covid-19. Protection lasted at least 6 months without an added boost. Vaccination was associated with mild-to-moderate adverse effects.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793, 1533-4406eISSN: 1533-4406DOI: 10.1056/NEJMoa2117608Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8849184
- Format
- –
- Schlagworte
- Ad26COVS1 - adverse effects, Ad26COVS1 - immunology, Adolescent, Adult, Confidence intervals, Coronavirus, Coronaviruses, COVID-19, COVID-19 - epidemiology, COVID-19 - mortality, COVID-19 - prevention & control, COVID-19 vaccines, Death, Double-Blind Method, Follow-Up Studies, Hospitalization - statistics & numerical data, Humans, Immunogenicity, Vaccine, Infectious Disease, Kaplan-Meier Estimate, Middle Aged, Original, Patient Acuity, Placebos, Population, Questionnaires, Safety, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2, Vaccine efficacy, Vaccine Efficacy - statistics & numerical data, Vaccines, Young Adult